As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...
Even as two amyloid immunotherapies are in clinical use, scientists still have many questions about how these antibodies affect the brain. Neuropathology and biomarker data from treated patients are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback